Foundation Medicine Expands ComboMATCH Participation with Blood-Based Biomarker Testing
核心洞察
Foundation Medicine has expanded its participation in the National Cancer Institute's ComboMATCH platform trials by including its FDA-approved blood-based biomarker test, FoundationOne Liquid CDx (搜索).
The initiative represents the largest biomarker-targeted cancer treatment combination testing program, aiming to identify promising treatments that can advance to larger clinical trials.
ComboMATCH tests whether genomically-guided therapy combinations may provide better patient outcomes than current standard of care for adults and children with cancer.
Foundation Medicine has announced its expanded participation in the National Cancer Institute's (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), now incorporating its FDA-approved blood-based biomarker test, FoundationOne Liquid CDx (搜索). The initiative, conducted in partnership with the ECOG-ACRIN Cancer Research Group (搜索), represents the largest biomarker-targeted cancer treatment combination testing program of its kind.
Enhanced Biomarker Testing Capabilities
The expansion builds upon Foundation Medicine's initial participation in ComboMATCH, which began in 2023 with the inclusion of its tissue-based biomarker test, FoundationOne CDx (搜索). As a participating Designated Laboratory, Foundation Medicine enables oncologists at ComboMATCH clinical sites to utilize patients' prior commercial testing results from both FoundationOne CDx and FoundationOne Liquid CDx (搜索) to help determine eligibility for treatment trials.
FoundationOne Liquid CDx (搜索) is an FDA-approved qualitative next-generation sequencing-based in vitro diagnostic test that analyzes 324 genes utilizing circulating cell-free DNA. The test is approved to report short variants in 311 genes, rearrangements in 8 genes, and copy number alterations in 3 genes, serving as a companion diagnostic to identify patients who may benefit from specific therapies.
Clinical Trial Framework and Objectives
ComboMATCH aims to identify promising treatment combinations that can advance to larger, more definitive clinical trials and improve patient outcomes. Each selected combination has strong pre-clinical or clinical evidence suggesting it could be more effective than either single agent alone. The initiative tests whether genomically-guided therapy combinations may provide better patient outcomes than current standard of care.
"The more we learn about how different cancers work and respond to treatment, the faster new targeted treatments and combinations can become available," said Dr. Amaya Gascó, Foundation Medicine's Vice President and Head of Clinical Development. "By using results from high quality biomarker tests like FoundationOne CDx (搜索) and FoundationOne Liquid CDx (搜索) to help determine trial eligibility for patients, ComboMATCH is connecting patients to the right trials for their unique cancer and informing more precise therapy options for complex cases to help improve patient outcomes."
Patient Enrollment Process
For patients interested in joining ComboMATCH treatment trials, enrollment begins with the patient registration trial through their oncologist. This protocol, managed by ECOG-ACRIN, contains rules for assigning patients to various treatment trials and other guidelines. Patients' tumor test results must show abnormalities being targeted by the drug combinations under study.
During registration, oncologists review FoundationOne CDx (搜索) or FoundationOne Liquid CDx (搜索) test results alongside other clinical information to determine trial eligibility. The treatment trials are conducted under an NCI-sponsored Investigational New Drug Application and led by NCI network groups including the Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group (搜索), NRG Oncology, and SWOG Cancer Research Network.
Foundation Medicine's Track Record
Foundation Medicine has been a key contributor to ComboMATCH since its opening, facilitating patient screening and enrollment through its biomarker testing capabilities. The company previously participated in the NCI's MATCH study from 2017 to 2023, a precursor to ComboMATCH that evaluated genomically-guided treatments targeting specific tumor alterations regardless of cancer type. Foundation Medicine served as the top designated laboratory for MATCH study enrollment, helping cast a wide net to evaluate potentially eligible patients.
The ComboMATCH initiative involves multiple pharmaceutical companies providing their agents for evaluation in treatment trials, representing a collaborative approach to advancing precision oncology research.